Next Webinar

​​​​Tuesday, February 28
1:00 -- 2:00 PM (EST)

PIONEER Trial: Prevention of Bleeding in AFib Patients Undergoing PCI

This month, we'll discuss the PIONEER AF-PCI trial, which looked at the effectiveness of rivaroxaban compared to warfarin to prevent bleeding in patients undergoing PCI. The results were published in the New England Journal of Medicine in December 2016.
To read an abstract of the trial click here.

Speaker: C. Michael Gibson, MD, Beth Israel Deaconess Medical Center, Boston

Sara Vazquez, PharmD, University of Utah
Diane Wirth, ANP, Grady Memorial Hospital

Register here

AC Forum Lunch & Learn Webinar Series

The AC Forum Lunch & Learn Webinar Series covers important and timely topics in anticoagulation care. The webinars are presented each month by international experts, and moderated by a multidisciplinary team.

Each one hour webinar is presented free of charge and is open to all healthcare professionals. You must pre-register by clicking on the registration link. In addition, all webinars are recorded and can be viewed below.

An archive of the AC Forum Lunch & Learn Webinar Series listed below.

Webinar Archive

Click the expand button located in the bottom right corner of webinar preview to enlarge the video to fullscreen.

Anticoagulant Therapy for Symptomatic Calf DVT (CACTUS)
January 11, 2017

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
Thursday, December 15

Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
October 25, 2016

Reducing the Hospital Burden of HIT: Impact of an Avoid-Heparin Program
Thursday, September 29

Guidance for the Practical Management of the Heparin Anticoagulants in the Treatment of VTE
August 17, 2016

NATF Atrial Fibrillation Consensus Document
Thursday, June 30

Effect of Body Weight on the Efficacy and Safety of the DOACs in VTE
May 12, 2016

Guidance for the Evaluation and Treatment of Hereditary and Acquired Thrombophilia
March 30, 2016

Guidance for the Prevention and Treatment of Cancer-Associated VTE
March 3, 2016

Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment
February 9, 2016

Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
January 20, 2016

The Changing Characteristics of Atrial Fibrillation Patients Treated with Warfarin
December 1, 2015

Clinical Monitoring of DOACs: "Site-Level Variation in and Practices Associated with Dabigatran Adherence"
October 20, 2015

Idarucizumab for Dabigatran Reversal
September 30, 2015

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
August 25, 2015

Clinical Characteristics & Outcomes with Rivaroxaban vs. Warfarin in Patients with NVAF but Underlying Native Mitral and Aortic Valve Disease Participating in the ROCKET AF Trial
June 16, 2015

Amiodarone, Anticoagulation, and Clinical Events in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial
May 14, 2015

Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation
March 17, 2015

An Evaluation of the Potential Drug Interaction Between Warfarin and Levothyroxine
February 19, 2015

Edoxaban vs Warfarin in Patients with Atrial Fibrillation
January 20, 2015

National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrilation
November 20, 2014

Patient Webinar –DVT and PE Discussion
in Honor of World Thrombosis Day

October 16, 2014

Antibiotic Interaction with Warfarin in the Ambulatory Setting
September 18, 2014

A Review of RE-COVER I and II: FDA Approves use of Dabigatran for treatment of acute VTE
June 19, 2014

Compression Stockings to Prevent Post-thrombotic Syndrome: A Randomized Placebo-controlled Trial
May 15, 2014

Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic
April 16, 2014

Anticoagulation Centers of Excellence: A Case-Based Demonstration
March 20, 2014

CLOTS3 Trial: AC Forum and Thrombosis Canada
September 19, 2013

FDA Postmarketing Report on Dabigatran
July 18, 2013